Nektar Therapeutics Share-based Payment Arrangement, Noncash Expense
Nektar Therapeutics (NKTR) reported Share-based Payment Arrangement, Noncash Expense of $4.56 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2015-08-06
- Nektar Therapeutics share-based payment arrangement, noncash expense for the quarter ending 2015-06-30 was $4.56M, a 9.51% increase year-over-year.
- Nektar Therapeutics share-based payment arrangement, noncash expense for the quarter ending 2015-03-31 was $5.18M, a 18.71% increase year-over-year.
- Nektar Therapeutics share-based payment arrangement, noncash expense for the quarter ending 2014-06-30 was $4.16M, a 4.41% decline year-over-year.
- Nektar Therapeutics share-based payment arrangement, noncash expense for the quarter ending 2014-03-31 was $4.36M, a 2.73% increase year-over-year.
- Nektar Therapeutics share-based payment arrangement, noncash expense for fiscal 2014 was $17.02M, a 3.90% decline from fiscal 2013.
- Nektar Therapeutics share-based payment arrangement, noncash expense for fiscal 2013 was $17.71M, a 9.32% increase from fiscal 2012.
- Nektar Therapeutics share-based payment arrangement, noncash expense for fiscal 2012 was $16.20M, a 14.22% decline from fiscal 2011.
- Nektar Therapeutics share-based payment arrangement, noncash expense for fiscal 2011 was $18.89M, a 8.54% increase from fiscal 2010.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2015-06-30 | $4.56M 10-Q · filed 2015-08-06 | $9.74M 10-Q · filed 2015-08-06 | ||
| 2015-03-31 | $5.18M 10-Q · filed 2015-05-01 | |||
| 2014-12-31 | $17.02M 10-K · filed 2015-02-26 | |||
| 2014-06-30 | $4.16M 10-Q · filed 2015-08-06 | $8.53M 10-Q · filed 2015-08-06 | $13.07M derived: sum of 3 quarters · filed 2015-08-06 | $17.63M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | $4.36M 10-Q · filed 2015-05-01 | $8.90M derived: sum of 2 quarters · filed 2015-05-01 | $13.47M derived: sum of 3 quarters · filed 2015-05-01 | $17.82M derived: sum of 4 quarters · filed 2015-05-01 |
| 2013-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $9.11M derived: sum of 2 quarters · filed 2015-02-26 | $13.46M derived: sum of 3 quarters · filed 2015-02-26 | $17.71M 10-K · filed 2015-02-26 |
| 2013-09-30 | $4.56M 10-Q · filed 2013-11-07 | $8.92M derived: sum of 2 quarters · filed 2014-08-01 | $13.16M 10-Q · filed 2013-11-07 | $17.35M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $8.60M 10-Q · filed 2014-08-01 | $12.79M derived: sum of 3 quarters · filed 2015-02-26 | $16.77M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $4.25M 10-Q · filed 2014-05-08 | $8.43M derived: sum of 2 quarters · filed 2015-02-26 | $12.41M derived: sum of 3 quarters · filed 2015-02-26 | $16.21M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $8.16M derived: sum of 2 quarters · filed 2015-02-26 | $11.96M derived: sum of 3 quarters · filed 2015-02-26 | $16.20M 10-K · filed 2015-02-26 |
| 2012-09-30 | $3.98M 10-Q · filed 2013-11-07 | $7.78M derived: sum of 2 quarters · filed 2013-11-07 | $12.02M 10-Q · filed 2013-11-07 | $16.40M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $8.04M 10-Q · filed 2013-08-09 | $12.42M derived: sum of 3 quarters · filed 2014-02-27 | $17.24M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $4.23M 10-Q · filed 2013-05-09 | $8.62M derived: sum of 2 quarters · filed 2014-02-27 | $13.44M derived: sum of 3 quarters · filed 2014-02-27 | $18.32M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $9.20M derived: sum of 2 quarters · filed 2014-02-27 | $14.08M derived: sum of 3 quarters · filed 2014-02-27 | $18.89M 10-K · filed 2014-02-27 |
| 2011-09-30 | $4.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $9.70M derived: sum of 2 quarters · filed 2012-11-09 | $14.50M 10-Q · filed 2012-11-09 | $19.18M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $9.68M 10-Q · filed 2012-08-09 | $14.37M derived: sum of 3 quarters · filed 2013-03-01 | $18.98M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $4.80M 10-Q · filed 2012-05-04 | $9.48M derived: sum of 2 quarters · filed 2013-03-01 | $14.10M derived: sum of 3 quarters · filed 2013-03-01 | $18.46M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $9.29M derived: sum of 2 quarters · filed 2013-03-01 | $13.65M derived: sum of 3 quarters · filed 2013-03-01 | $17.40M 10-K · filed 2013-03-01 |
| 2010-09-30 | $4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $8.97M derived: sum of 2 quarters · filed 2011-11-04 | $12.72M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $8.11M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $3.74M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $10.33M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |